Clarus Therapeutics Inc. and Blue Water Acquisition Corp. on April 27 announced a definitive business combination agreement that will result in Clarus becoming a publicly traded company. 

For years, you’ve been replacing your patient’s testosterone. Maybe it’s time to consider replacing how it’s delivered. While there have been frequent, and prominent, new products developed for treating hypogonadism in the last 20 years, one particular type of option has been scarce – and it may be the one that patients want and/or prefer. […]